Medications for Transthyretinmediated Amyloidosis

1 result
  • vyndaqel

    (tafamidis meglumine)
    Pfizer Laboratories Div Pfizer Inc
    VYNDAQEL and VYNDAMAX are indicated for treating the cardiomyopathy associated with wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults, aiming to reduce cardiovascular mortality and related hospitalizations.